AstraZeneca’s Enhertu Cancer Treatment to Be Included in China’s Health Insurance
The Chinese government has announced that AstraZeneca’s widely recognized breast cancer treatment, Enhertu, will be incorporated into its state-funded health insurance program starting at the beginning of next year. This addition to the national reimbursement list will enhance accessibility to the medication for the general public in China. However, it is important to note that…